Overview

Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nilotinib is effective in the prophylaxis and treatment of CMV reactivation in allo-HSCT patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital